Patents Assigned to President National Cancer Center
  • Nucleic acids encoding HST 2 muteins
    Patent number: 6013784
    Abstract: The present invention provides a polypeptide represented by the following amino acid sequence:(Met)n=X=Leu=Ala=Gly=Glu=Ile=Ala=Gly=Val=Asn - Trp=Glu=Ser - Gly=Tyr=Leu=Val=Gly=Ile=Lys=Arg=Gln=Arg=Arg - Leu=Tyr=Cys=Asn - Val=Gly=Ile=Gly=Phe=His=Leu=Gln=Val=Leu=Pro - Asp=Gly=Arg=Ile - Ser=Gly=Thr=His=Glu=Glu=Asn=Pro=Tyr=Ser=Leu - Leu=Glu=Ile=Ser - Thr=Val=Glu=Arg=Gly=Val=Val=Ser=Leu=Phe=Gly - Val=Arg=Ser=Ala - Leu=Phe=Val=Ala=Met=Asn=Ser=Lys=Gly=Arg=Leu - Tyr=Ala=Thr=Pro - Ser=Phe=Gin=Glu=Glu=Cys=Lys=Phe=Arg=Glu=Thr Leu=Leu=Pro=Asn - Asn=Tyr=Asn=Ala=Tyr=Glu=Ser=Asp=Leu=Tyr=Gln - Gly=Thr=Tyr=Ile - Ala=Leu=Ser=Lys=Tyr=Gly=Arg=Val=Lys=Arg=Gly - Ser=Lys=Val=Ser - Pro=Ile=Met=Thr=Val=Thr=His=Phe=Leu=Pro=Arg=Ile wherein n is 0 or 1 and X represents Pro Ala Gly Thr Arg Ala Asn Asn Thr Leu Leu Asp Ser Arg Gly Trp Gly Thr Leu Leu Ser Arg Ser Arg Ala Gly or a fragment thereof (n=0: SEQ ID NO: 1, n=1: SEQ ID NO: 2), a recombinant DNA coding for the polypeptide, a vector containing the recombinant DNA, the preparation of a
    Type: Grant
    Filed: July 29, 1997
    Date of Patent: January 11, 2000
    Assignee: President of National Cancer Center
    Inventors: Koji Yoshimura, Kaori Ishimaru, Koichi Igarashi, Masaaki Terada
  • Human s-myc-like polypeptide and a gene coding for said polypeptide
    Patent number: 5861307
    Abstract: Human s-myc-like gene, mycL2 (SEQ ID NO: 3) was isolated and identified from human placenta genomic DNA by PCR and human s-Myc-like polypeptide MycL2 (SEQ ID NO: 2) as the expression product of the gene was identified. The genetic DNA embedded in liposome can be targeted to glioma cells to prevent the growth of tumor cells or cause apotosis.
    Type: Grant
    Filed: August 24, 1995
    Date of Patent: January 19, 1999
    Assignees: President of National Cancer Center, Nippon Kayaku Kabushiki Kaisha
    Inventors: Yoshiyuki Kuchino, Shigehide Kagaya
  • Hst-2 muteins, pharmaceutical compositions and kits comprising same, and preparation of same
    Patent number: 5679550
    Abstract: The present invention provides a polypeptide represented by the following amino acid sequence: ##STR1## wherein n is 0 or 1 and X represents Pro Ala Gly Thr Arg Ala Asn Asn Thr Leu Leu Asp Ser Arg Gly Trp Gly Thr Leu Leu Ser Arg Ser Arg Ala Gly or a fragment thereof (n=0: SEQ ID NO:1, n=1: SEQ ID NO:2), a recombinant DNA coding for the polypeptide, a vector containing the recombinant DNA, the preparation of a transformant carrying the vector, and the production of the polypeptide with the transformant. The use of this peptide in pharmaceutical compositions is also provided.
    Type: Grant
    Filed: October 31, 1995
    Date of Patent: October 21, 1997
    Assignees: Takeda Chemical Industries, Inc., President of National Cancer Center
    Inventors: Koji Yoshimura, Kaori Ishimaru, Koichi Igarashi, Masaaki Terada
  • Deletion muteins of hst-1
    Patent number: 5639862
    Abstract: A deletion type mutein of heparin-binding secretory transforming factor (hst-1) possesses excellent cell growth promoting activity and is stable. The present mutein can therefore be used as a therapeutic medicine such as a healing promoter for burns, wounds, surgical injuries etc.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: June 17, 1997
    Assignees: President of National Cancer Center, Takeda Chemical Industries, Ltd.
    Inventors: Masaaki Terada, Hiromi Sakamoto, Teruhiko Yoshida, Koichi Igarashi, Yoshio Kozai